论文部分内容阅读
纤溶酶原激活剂(t-PA)是纤溶系统主要的生理性激活剂,它的活性受特异性抑制物(PAI)调节。近年来,国产蛇毒抗栓酶(Svate)已用于血栓性疾病的治疗,有降低血浆纤维蛋白原、全血粘度,降血脂、抑制血小板等作用。本研究观察了52例AMI患者,其中22例采用常规治疗,15例采用Svate溶栓治疗(首剂3～5U,以后0.75U给药14天),15例国产尿激酶(UK)溶栓治疗(75～120万U),24名无心血管系统疾病年龄相仿的健康人做对照观察。AMI患者分别在入院时、用药后即刻、革2、3、7、14、21天采集静脉血,
Plasminogen activator (t-PA) is a major physiological activator of fibrinolytic system and its activity is regulated by a specific inhibitor (PAI). In recent years, domestic snake venom antithrombin enzyme (Svate) has been used in the treatment of thrombotic diseases, lower plasma fibrinogen, whole blood viscosity, lipid-lowering, inhibition of platelet and so on. In this study, 52 patients with AMI were observed, of whom 22 were treated routinely, 15 were treated with Svate thrombolytic therapy (3 to 5 U for the first dose and 0.75 U for 14 days thereafter) and 15 for thrombolytic therapy with urokinase (UK) (75 ~ 1.2 million U), 24 healthy people without cardiovascular disease similar age control. AMI patients were admitted to hospital, immediately after treatment, leather 2,3,7,14,21 days to collect venous blood,